Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

2024年3月14日 · Sorafenib is used in adults to treat liver cancer, thyroid cancer, or kidney cancer. Sorafenib may also be used for purposes not listed in this medication guide.

Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. How should this medicine be used? Sorafenib comes as a tablet to take by mouth. It is usually taken twice a day.

2011年3月1日 · The ACC inhibitor, soraphen A, lowers cellular malonyl CoA, attenuates DNL and the formation of fatty acid elongation products derived from exogenous fatty acids, i.e., 16:0 and 18:2, n-6; IC (50)∼5nM.

Generic Name Sorafenib DrugBank Accession Number DB00398 Background. Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. 1 First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ...

Sorafenib is a medication that stops cancer cells from growing. It treats liver cancer, kidney cancer and thyroid cancer. This medication comes as a tablet that you can take by mouth with a glass of water as directed. Take it on an empty stomach. What is this medication?

Indicated for locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) that is refractory to radioactive iodine treatment. 400 mg PO q12hr. Dosage modification for DTC....

2024年12月10日 · Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive,differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Monitor electrolytes and ECG in patients with congestive heart failure or bradyarrhythmias and in those receiving concomitant therapy with drugs known to prolong the QT interval (e.g., class Ia and III antiarrhythmics); correct electrolyte abnormalities (magnesium, potassium, calcium).

Sorafenib (Nexavar®) belongs to a group of targeted therapy drugs called angiogenesis inhibitors and cancer growth inhibitors. It is best to read our information about sorafenib (Nexavar®) with our general information about targeted therapy drugs and the type of cancer you have.